Table 1.
Baseline Characteristics for Patients With CS and APAs for Whom PAT Samples Were Available
| Sex | Age | Diagnosis | BMI | Diurnal Cortisol |
Chol | TG | Glucose | Mutations | |
|---|---|---|---|---|---|---|---|---|---|
| MN | 8 am | ||||||||
| F | 46 | APA | 27.9 | NA | NA | NA | NA | NA | |
| F | 59 | APA | 21.4 | NA | NA | 189 | 111 | 82 | |
| M | 54 | APA | 26.4 | 5.3 | 15.1 | 196 | NA | 103 | |
| M | 58 | APA | 36.4 | 8.9 | NA | 189 | 216 | 94 | |
| M | 63 | APA | 27.6 | NA | NA | 162 | 74 | 126 | MEN1 |
| M | 64 | APA | NA | 16.5 | 3.9 | 220 | NA | 93 | |
| F | 14 | CPA | 42.6 | 32.4 | 30.4 | 174 | 126 | 114 | |
| F | 14 | CPA | 24.5 | 22.3 | 20 | 224 | 81 | 84 | |
| F | 15 | CPA | NA | 19.6 | 17.9 | 159 | 158.5 | 0.57 | |
| F | 16 | CPA | 20.5 | 21.3 | 18.8 | 172 | 124.5 | 85 | |
| F | 27 | CPA | 36.4 | 6 | 8.5 | 289 | 61 | 102 | |
| F | 36 | CPA | 29.7 | NA | NA | 207 | 114 | NA | |
| F | 44 | CPA | 24.4 | NA | NA | 169 | 197 | 105 | |
| F | 51 | CPA | 32.7 | 13 | 18.8 | 204 | NA | 89 | |
| F | 53 | CPA | 36.8 | 8.9 | 10.4 | 163 | 81 | 85 | |
| F | 66 | CPA | 26.1 | NA | NA | 203 | 80 | 104 | |
| F | 8 | iMAD | 28 | 32.9 | 31.1 | 161 | 61 | 79 | |
| F | 10 | iMAD | 37.1 | 20.6 | 19.8 | NA | 91 | NA | PDE11A |
| F | 37 | iMAD | NA | NA | NA | NA | NA | NA | |
| F | 30 | MMAD | 39.9 | 21.5 | 23.3 | 351 | NA | 107 | |
| F | 42 | MMAD | NA | 30.5 | 21.8 | 273 | 125.5 | 120 | |
| F | 46 | MMAD | 33.5 | 24.4 | 22.8 | NA | 87 | 129 | |
| F | 49 | MMAD | NA | 29.3 | 32.5 | NA | NA | NA | |
| F | 49 | MMAD | 29.9 | 16.7 | 14.3 | 152 | NA | 90 | |
| F | 50 | MMAD | 40.9 | 9.5 | 8.3 | 143 | 101.5 | 90 | |
| F | 53 | MMAD | 35.7 | 22.5 | 20.6 | 234 | 161.5 | 134 | |
| F | 57 | MMAD | 19.4 | 22.6 | 31.4 | 217 | 122 | 94 | |
| F | 66 | MMAD | 37.2 | 12 | 30.5 | 224 | 147.5 | 80 | |
| M | 45 | MMAD | 38.2 | 10 | 6.7 | 269 | 169.5 | 142 | |
| M | 47 | MMAD | 39.5 | 10.4 | 8.6 | 192 | 89 | NA | |
| M | 54 | MMAD | 34.6 | 15.4 | 5.5 | NA | 190 | 87 | |
| F | 10 | mtPPNAD | 22.2 | 23.9 | 21.1 | 167 | 71 | 92 | PRKAR1A |
| F | 10 | mtPPNAD | 22.8 | 2.7 | 17.2 | 162 | 69.5 | 91 | PRKAR1A |
| F | 17 | mtPPNAD | 26.8 | 4.3 | 12.3 | 162 | 88.5 | 80 | PRKAR1A |
| F | 19 | mtPPNAD | 30.6 | 13 | 10.6 | 201 | 104 | 124 | PRKAR1A |
| F | 20 | mtPPNAD | 26.6 | 30.1 | 25.4 | 200 | 81 | 67 | PRKAR1A |
| F | 22 | mtPPNAD | 30.4 | 30.8 | 34.5 | 171 | 33 | NA | PRKAR1A |
| F | 23 | mtPPNAD | 37.2 | 31 | 31 | NA | NA | 110 | PRKAR1A |
| F | 25 | mtPPNAD | 38.4 | 28.1 | 29.1 | 223 | NA | 79 | PRKAR1A |
| F | 28 | mtPPNAD | 25.7 | 13.6 | 12.8 | 123 | 61 | 88 | PRKAR1A |
| F | 31 | mtPPNAD | 23.7 | 8.5 | 3.1 | 161 | 84.5 | 78 | PRKAR1A |
| F | 51 | mtPPNAD | 23 | 10.4 | 11.7 | NA | 91 | 103 | PRKAR1A |
| M | 13 | mtPPNAD | 31.4 | 3.8 | 7.5 | 165 | 96.5 | 81 | PRKAR1A |
| M | 58 | mtPPNAD | 40.7 | 5.8 | 16.2 | 159 | 193 | 104 | PRKAR1A |
| F | 3 | PPNAD | 19.1 | 20 | 21 | 184 | 82 | 83 | |
| F | 4 | PPNAD | 16 | 6.5 | 14.1 | 143 | 40 | 79 | |
| F | 6 | PPNAD | 22.6 | 52.5 | 40.7 | 157 | 44 | 86 | |
| F | 17 | PPNAD | 25.3 | 1.1 | 6.2 | 212 | 78 | 88 | |
| M | 16 | PPNAD | 28.1 | 15.1 | 17.1 | 275 | 97.5 | 94 | |
| M | 19 | PPNAD | 24.3 | 22.3 | 21.9 | 233 | 62 | 77 | |
Abbreviations: Chol, cholesterol; F, female; Gluc, glucose; iMAD, isolated micronodular adrenocortical hyperplasia; M, male; MMAD, massive macronodular adrenocortical disease; MN, midnight; mtPPNAD, primary pigmented nodular adrenocortical disease (with PRKAR1A mutations); NA, not applicable; TG, serum triglycerides. All measurements were performed preoperatively within the week before adrenalectomy.